Market Overview

Agilent Announces Update on PD-L1 CE-IVD in Urothelial Carcinoma

Share:

PD-L1 IHC 22C3 pharmDx Can Now Be Used as an Aid to Identify
Urothelial Carcinoma Patients for Treatment With KEYTRUDA®
(pembrolizumab)

Agilent
Technologies Inc.
(NYSE:A) today announced that its PD-L1 IHC 22C3
pharmDx assay is now labeled for an updated use in urothelial carcinoma
in Europe.

Physicians in Europe can now use the assay as an aid to identify
urothelial carcinoma patients who are ineligible for cisplatin and may
respond to KEYTRUDA (pembrolizumab) as a first-line treatment option.
KEYTRUDA is a targeted anti-PD-1 immunotherapy manufactured by Merck
(known as MSD outside the United States and Canada). It is a humanized
monoclonal antibody that may increase the ability of the body's immune
system to help detect and fight tumor cells.

"We are pleased that PD-L1 IHC 22C3 pharmDx will help physicians
identify urothelial carcinoma patients for whom KEYTRUDA may be an
appropriate first-line treatment option. Being able to support the use
of immuno-oncology therapeutics by bringing their associated diagnostics
to market is truly encouraging," said Sam Raha, president of Agilent's
Diagnostics and Genomics Group.

Agilent is a worldwide leader in partnering with pharmaceutical
companies to develop immunohistochemical-based diagnostics for cancer
therapy. Agilent developed PD-L1 IHC 22C3 pharmDx in partnership with
Merck. PD-L1 expression in urothelial carcinoma tissues is interpreted
using Combined Positive Score (CPS). PD-L1 IHC 22C3 pharmDx also helps
physicians identify non-small cell lung cancer (NSCLC) patients for
treatment with KEYTRUDA. PD-L1 expression in NSCLC tissues is
interpreted using Tumor Proportion Score (TPS).

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A) is a global leader in life sciences,
diagnostics, and applied chemical markets. With more than 50 years of
insight and innovation, Agilent instruments, software, services,
solutions, and people provide trusted answers to customers' most
challenging questions. The company generated revenues of $4.47 billion
in fiscal 2017 and employs 14,200 people worldwide. Information about
Agilent is available at www.agilent.com.
To receive the latest Agilent news, subscribe to our Newsroom.

View Comments and Join the Discussion!